MYGN

4.75

2.37% 0.11

시간 외 거래: 4.74 -0.010 -0.21%

Myriad Genetics Inc (MYGN)

개요 뉴스 가격 이력 옵션 체인 Financials MYGN 왜 하락? 토론 예측 주식 분할

전일 마감가:

$4.64

열려 있는:

$4.54

하루 거래량:

1.77M

Relative Volume:

1.37

시가총액:

$444.16M

수익:

$824.50M

순이익/손실:

$-365.90M

주가수익비율:

-1.2016

EPS:

-3.9531

순현금흐름:

$-25.60M

1주 성능:

-2.06%

1개월 성능:

+8.45%

6개월 성능:

-38.87%

1년 성능:

-52.17%

1일 변동 폭

$4.54

$4.80

1주일 범위

$4.38

$5.0499

52주 변동 폭

$3.76

$10.30

Myriad Genetics Inc Stock (MYGN) Company Profile

명칭

Myriad Genetics Inc

부문

Healthcare (1114)

산업

Diagnostics & Research (53)

전화

801-584-3600

주소

322 NORTH 2200 WEST, SALT LAKE CITY, UT

직원

2,700

트위터

@myriadgenetics

다음 수익 날짜

2025-02-24

최신 SEC 제출 서류

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
MYGN Myriad Genetics Inc	4.75	433.88M	824.50M	-365.90M	-25.60M	-3.9531
TMO Thermo Fisher Scientific Inc	470.21	172.63B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	190.11	135.42B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	579.85	45.95B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	111.75	31.51B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	299.57	28.94B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2025-05-21	다운그레이드	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-05-07	다운그레이드	Wells Fargo	Overweight → Equal Weight
2025-04-09	다운그레이드	Guggenheim	Buy → Neutral
2025-03-12	업그레이드	Piper Sandler	Neutral → Overweight
2025-02-12	개시	Craig Hallum	Buy
2024-12-10	개시	UBS	Neutral
2024-12-09	다운그레이드	Leerink Partners	Outperform → Market Perform
2024-09-19	개시	Morgan Stanley	Equal-Weight
2024-08-28	개시	Wells Fargo	Overweight
2024-06-27	개시	Scotiabank	Sector Outperform
2024-06-03	재개	Jefferies	Underperform
2024-05-08	업그레이드	Leerink Partners	Market Perform → Outperform
2023-12-21	재개	Piper Sandler	Neutral
2023-12-19	개시	Wells Fargo	Equal Weight
2023-12-14	개시	Guggenheim	Buy
2023-12-13	개시	Wolfe Research	Outperform
2023-07-05	재개	JP Morgan	Underweight
2023-05-23	업그레이드	Goldman	Sell → Buy
2023-01-18	업그레이드	Raymond James	Mkt Perform → Outperform
2022-10-06	개시	Stephens	Equal-Weight
2021-10-15	재개	Cowen	Market Perform
2021-06-15	개시	Raymond James	Mkt Perform
2021-06-03	개시	Goldman	Sell
2019-09-26	다운그레이드	BofA/Merrill	Neutral → Underperform
2019-08-14	다운그레이드	Piper Jaffray	Overweight → Neutral
2019-08-02	업그레이드	BofA/Merrill	Underperform → Neutral
2019-08-01	업그레이드	Barclays	Underweight → Equal Weight
2019-07-29	다운그레이드	Needham	Strong Buy → Hold
2019-07-09	다운그레이드	Cowen	Outperform → Market Perform
2019-03-12	재확인	Needham	Strong Buy
2019-01-03	개시	Needham	Strong Buy
2018-11-30	업그레이드	Goldman	Sell → Neutral
2018-10-10	업그레이드	Piper Jaffray	Neutral → Overweight
2018-07-11	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	업그레이드	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	개시	Goldman	Sell
2018-01-22	재확인	Barclays	Equal Weight
2018-01-05	개시	BTIG Research	Buy
2017-10-02	재개	Leerink Partners	Mkt Perform
2017-08-09	재확인	Barclays	Equal Weight
2017-02-08	업그레이드	Ladenburg Thalmann	Sell → Neutral
2017-01-18	개시	Deutsche Bank	Sell
2016-10-10	다운그레이드	Ladenburg Thalmann	Neutral → Sell

모두보기

Myriad Genetics Inc 주식(MYGN)의 최신 뉴스

09:45 AM

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance

09:45 AM

Mar 18, 2026

Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union

Mar 18, 2026

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Mar 18, 2026

Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN

Mar 18, 2026

Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - Investing.com South Africa

Mar 18, 2026

Mar 17, 2026

FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - GuruFocus

Mar 17, 2026

Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com

Mar 17, 2026

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times

Mar 17, 2026

FDA approves genetic test to match ovarian cancer patients to Zejula - Stock Titan

Mar 17, 2026

Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS

Mar 16, 2026

Mar 15, 2026